Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums

User menu

  • My alerts

Search

  • Advanced search
The College of Family Physicians of Canada
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums
  • My alerts
The College of Family Physicians of Canada

Advanced Search

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • RSS feeds
  • Follow cfp Template on Twitter
OtherFP Watch

Bisphosphonate-associated osteonecrosis of the jaw

Aliya Khan
Canadian Family Physician July 2008, 54 (7) 1019-1021;
Aliya Khan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: avkhan@aol.com
  • Article
  • Figures & Data
  • eLetters
  • Info & Metrics
  • PDF
Loading

In 2003, the first reports describing osteonecrosis of the jaw in patients receiving bisphosphonates were published.1 About 95% of these cases occurred among cancer patients receiving high-dose intravenous bisphosphonates. Approximately 5% of the reported cases have been in osteoporosis patients receiving low-dose bisphosphonate therapy.2

The Canadian Task Force on Osteonecrosis of the Jaw, with representatives from medical, surgical, and pathology disciplines, has developed Canadian consensus practice guidelines for bisphosphonate-associated osteonecrosis of the jaw.3 These guidelines are based on a systematic review of the literature.

Osteonecrosis of the jaw is an uncommon condition with many recognized causes. Traditionally, it has been associated with head and neck irradiation. It can also occur in the presence of periodontal disease, local malignancy, chemotherapy, glucocorticoid therapy, or trauma.1–6 Recently, however, high-dose intravenous bisphosphonates have been identified as a risk factor for osteonecrosis of the jaw among oncology patients. Low-dose bisphosphonate use in patients with osteoporosis or other metabolic bone disease has not been causally linked to the development of osteonecrosis of the jaw.

Bisphosphonates have been widely used in the management of osteoporosis and metabolic bone disease. They have proven to be effective in reducing the risk of fracture and have recently been shown to improve mortality.7 They are valuable in the management of skeletal complications of malignancy, namely metastatic bone disease and hypercalcemia of malignancy, and are a key treatment option for cancer patients with metastatic disease.8–14

The mechanism by which bisphosphonates might contribute to the development of osteonecrosis of the jaw is not well understood. Osteonecrosis of the jaw can occur in patients who are not taking bisphosphonates and in patients without traditional risk factors.

Diagnosis

If exposed bone is present in the maxillofacial region for more than 8 weeks in the absence of radiotherapy to the jaw in a patient who has been on bisphosphonate therapy, the diagnosis can be confirmed clinically. It is important to exclude other conditions that can present similarly. These include local malignancy, trauma, periodontal disease, and lingual mandibular sequestration and ulceration.15 Lingual mandibular sequestration and ulceration is a spontaneous sequestration that was described before the availability of amino bisphosphonates. It is a self-limiting process that spontaneously heals within 3 days to 12 weeks.16

Incidence

Among cancer patients receiving high-dose intravenous bisphosphonates, osteonecrosis of the jaw is dependent on dose and duration of therapy,17–20 and has an estimated incidence of 1% to 12%.17,21–24 Among osteoporosis patients, bisphosphonate-associated osteonecrosis of the jaw is rare and the incidence might not be greater than the natural background incidence of the condition. Postmarketing data and observational studies indicate an estimated incidence of less than 1 case per 100 000 person-years of exposure to oral amino bisphosphonates.25

Prevention and treatment

All patients receiving bisphosphonate therapy should ensure that they maintain good oral hygiene and follow the Canadian Dental Association recommendations of semiannual visits to their dentists.26 Quitting smoking and limiting alcohol intake should be encouraged. Before starting intravenous bisphosphonate therapy for a cancer patient, a detailed examination and panoramic x-ray scans of the oral cavity should be completed. If an invasive procedure is necessary while on high-dose intravenous bisphosphonate therapy, the bisphosphonate treatment should be interrupted, if medically possible, and any essential dental work should be completed (Figure 126). Ideally, bisphosphonate therapy should be stopped during the healing period.27,28

Figure 1
  • Download figure
  • Open in new tab
Figure 1 Bisphosphonate-associated osteonecrosis of the jaw following a palliative resection of the mandible with insertion of a reconstruction plate

Progressive tissue necrosis has resulted in continued exposure of the bone and reconstruction plate, despite attempts to keep the wound clean.

Reprinted with permission from the Journal of the Canadian Dental Association26 and Dr George Sandor, Professor of Oral and Maxillofacial Surgery, Clinical Director, Graduate Training Programme in Oral and Maxillofacial Surgery and Anesthesia, University of Toronto and Mount Sinai Hospital.

For osteoporosis patients requiring urgent oral surgery, interruption of bisphosphonate therapy is recommended during the healing period. If surgery is not urgent, then bisphosphonate treatment can be discontinued for several months before the planned procedure and restarted when healing is complete.29,30

Treatment of osteonecrosis of the jaw currently focuses on addressing local pain, treating secondary infection, and ensuring adequate nutritional intake and appropriate dietary supplementation (using a feeding tube, if necessary). It is recommended that surgery be limited to removing necrotic debris.31

Conclusion

Bisphosphonate-associated osteonecrosis of the jaw is an important condition seen most commonly in oncology patients receiving high-dose intravenous bisphosphonates. Low-dose bisphosphonates given either orally or intravenously in osteoporosis patients have not been causally linked to the development of osteonecrosis of the jaw. A temporal relationship between high-dose intravenous bisphosphonates and osteonecrosis of the jaw exists in cancer patients.

As the condition can occur spontaneously in the absence of known risk factors and the background incidence is not known, it is important to ensure that all patients maintain good dental hygiene and see their dentists semiannually. Prospective data will provide a greater understanding of the pathogenesis and the true incidence of osteonecrosis of the jaw occurring in association with bisphosphonates, as well as the background incidence of spontaneous osteonecrosis of the jaw.

Acknowledgment

The development of the Canadian guidelines on osteonecrosis of the jaw was funded by the Canadian Association of Oral and Maxillofacial Surgeons’ Foundation for Continuing Education and Research. The Canadian Task Force on Osteonecrosis of the Jaw comprises the following members: Aliya A. Khan, George K.B. Sandor, Edward Dore, Archibald D. Morrison, Mazen Alsahli, Faizan Amin, Edmund Peters, David A. Hanley, Sultan R. Chaudry, David W. Dempster, Francis H. Glorieux, Alan J. Neville, Reena M. Talwar, Cameron M. Clokie, Majd Al Mardini, Terri Paul, Sundeep Khosla, Robert G. Josse, Susan Sutherland, David K. Lam, Robert P. Carmichael, Nick Blanas, David Kendler, Steven Petak, Louis Georges Ste-Marie, Jacques Brown, A. Wayne Evans, Lorena Rios, Brian Lentle, and Juliet E. Compston. The consensus practice guidelines have been endorsed by the following national and international societies: the Canadian Association of Oral and Maxillofacial Surgeons, the Canadian Society of Endocrinology and Metabolism, the Ontario Society of Oral and Maxillofacial Surgeons, the Canadian Academy of Oral and Maxillofacial Pathology and Oral Medicine, the American Association of Clinical Endocrinologists, the International Bone and Mineral Society, and the International Society of Clinical Densitometry.

Footnotes

  • Competing interests

    Dr Khan is a consultant for Amgen, Novartis, Merck, Lilly, Procter & Gamble, and Servier, and has received research support from Merck, Novartis, and Procter & Gamble.

  • Copyright© the College of Family Physicians of Canada

References

  1. ↵
    MarxREPamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemicJ Oral Maxillofac Surg200361911157
    OpenUrlCrossRefPubMed
  2. ↵
    FavusMJDiabetes and the risk of osteonecrosis of the jaw [editorial]J Clin Endocrinol Metab20079238178
    OpenUrlCrossRefPubMed
  3. ↵
    KhanAASándorGKBDoreEMorrisonADAlsahliMAminFCanadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jawJ Rheumatol2008Jun 1Epub ahead of print. Available from: http://jrheum.com/earlyrelease.htmlAccessed 2008 May 30
  4. Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral and Maxillofacial SurgeonsAmerican Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jawsJ Oral Maxillofac Surg200765336976
    OpenUrlCrossRefPubMed
  5. RuggieroSLMehrotraBRosenbergTJEngroffSLOsteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 casesJ Oral Maxillofac Surg200462552734
    OpenUrlCrossRefPubMed
  6. ↵
    KademaniDKokaSLacyMQRajkumarSVPrimary surgical therapy for osteonecrosis of the jaw secondary to bisphosphonate therapyMayo Clin Proc200681811003
    OpenUrlCrossRefPubMed
  7. ↵
    LylesKWColón-EmericCSMagazinerJSAdachiJDPieperCFMautalenCZoledronic acid in reducing clinical fracture and mortality after hip fractureN Eng J Med2007111nihpa40967
  8. ↵
    BrownJPJosseRGScientific Advisory Council of the Osteoporosis Society of Canada: 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in CanadaCMAJ200216710 SupplS134
    OpenUrlPubMed
  9. BerensonJRHillnerBEKyleRAAndersonKLiptonAYeeGCAmerican Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myelomaJ Clin Oncol20022017371936
    OpenUrlAbstract/FREE Full Text
  10. BerrySWaldronTWinquistELukkaHThe use of bisphosphonates in men with hormone-refractory prostate cancer Practice guideline report No. 3–14Toronto, ONCancer Care Ontario2005Available from: www.cancercare.on.ca/pdf/pebc3-14s.pdfAccessed 2008 May 30
  11. BerrySWaldronTWinquistELukkaHThe use of bisphosphonates in men with hormone-refractory prostate cancer: a systematic review of randomized trialsCan J Urol200613431808
    OpenUrlPubMed
  12. HillnerBEIngleJNChlebowskiRGralowJYeeJCJanjanNAAmerican Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancerJ Clin Oncol20032121404257
    OpenUrlAbstract/FREE Full Text
  13. KyleRAYeeGCSomerfieldMRFlynnPJHalabiSJagannathSAmerican Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myelomaJ Clin Oncol20072517246472
    OpenUrlAbstract/FREE Full Text
  14. ↵
    SaadFGleasonDMMurrayRTchekmedyianSVennerPLacombeLA randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinomaJ Natl Cancer Inst20029419145868
    OpenUrlAbstract/FREE Full Text
  15. ↵
    KhoslaSBurrDCauleyJDempsterDWEbelingPRFelsenbergDBisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral ResearchJ Bone Miner Res20072210147991
    OpenUrlCrossRefPubMed
  16. ↵
    PetersELovasGLWysockiGPLingual mandibular sequestration and ulcerationOral Surg Oral Med Oral Pathol199375673943
    OpenUrlCrossRefPubMed
  17. ↵
    BamiasAKastritisEBamiaCMoulopoulosLAMelakopoulosIBozasGOsteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factorsJ Clin Oncol2005233485807
    OpenUrlAbstract/FREE Full Text
  18. MarxRESawatariYFortinMBroumandVBisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatmentJ Oral Maxillofac Surg20056311156775
    OpenUrlCrossRefPubMed
  19. MavrokokkiTChengASteinBGossANature and frequency of bisphosphonate-associated osteonecrosis of the jaws in AustraliaJ Oral Maxillofac Surg200765341523
    OpenUrlCrossRefPubMed
  20. ↵
    DimitrakopoulosIMagopoulosCKarakasisDBisphosphonate-induced avascular osteonecrosis of the jaws: a clinical report of 11 casesInt J Oral Maxillofac Surg200635758893
    OpenUrlCrossRefPubMed
  21. ↵
    CafroAMBarbaranoLAAndrianiAOsteonecrosis of the jaw associated with chronic bisphosphonates therapy: an Italian experience [abstract]Blood2005106115152a
    OpenUrl
  22. DimopoulosMAKastritisEAnagnostopoulosAMelakopoulosIGikaDMoulopoulosLAOsteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acidHaematologica200691796871
    OpenUrlAbstract/FREE Full Text
  23. DurieBGKatzMCrowleyJOsteonecrosis of the jaws and bisphosphonatesN Engl J Med2005353199102
    OpenUrlCrossRefPubMed
  24. ↵
    TosiPZamagniECanginiDTacchettiPOffidaniMRonconiSBisphosphonates and osteonecrosis of the jaws: incidence in a homogeneous series of patients with newly diagnosed multiple myeloma treated with zoledronic acid [abstract]Blood2005106113461a
    OpenUrl
  25. ↵
    FelsenbergDHoffmeisterBAmilingMBisphosphonattherapie assoziierteKiefernekrosen Deutsches ArzteblattIn press
  26. ↵
    LamDKSándorGKHolmesHIEvansAWClokieCMA review of bisphosphonate-associated osteonecrosis of the jaws and its managementJ Can Dent Assoc200773541722
    OpenUrlPubMed
  27. ↵
    KyleRAYeeGCSomerfieldMRFlynnPJHalabiSJagannathSAmerican Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myelomaJ Clin Oncol20072517246472
    OpenUrlAbstract/FREE Full Text
  28. ↵
    ZavrasAIZhuSBisphosphonates are associated with increased risk for jaw surgery in medical claims data: is it osteonecrosis?J Oral Maxillofac Surg200664691723
    OpenUrlCrossRefPubMed
  29. ↵
    MeloMObeidGOsteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy. Strategies for prevention and early recognitionJ Am Dent Assoc200513612167581
    OpenUrlAbstract/FREE Full Text
  30. ↵
    RuggieroSGralowJMarxREHoffAOSchubertMMHurynJMPractical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancerJ Oncol Pract200621714
    OpenUrlAbstract/FREE Full Text
  31. ↵
    FarahCSSavageNWOral ulceration with bone sequestrationAust Dent J2003481614
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

Canadian Family Physician: 54 (7)
Canadian Family Physician
Vol. 54, Issue 7
1 Jul 2008
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on The College of Family Physicians of Canada.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Bisphosphonate-associated osteonecrosis of the jaw
(Your Name) has sent you a message from The College of Family Physicians of Canada
(Your Name) thought you would like to see the The College of Family Physicians of Canada web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Bisphosphonate-associated osteonecrosis of the jaw
Aliya Khan
Canadian Family Physician Jul 2008, 54 (7) 1019-1021;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Bisphosphonate-associated osteonecrosis of the jaw
Aliya Khan
Canadian Family Physician Jul 2008, 54 (7) 1019-1021;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Diagnosis
    • Incidence
    • Prevention and treatment
    • Conclusion
    • Acknowledgment
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Ocular side effects of bisphosphonates: A case report and literature review
  • Google Scholar

More in this TOC Section

  • Use of nonvitamin dietary supplements with prescription medications
  • Elliptical excision
  • Hospitalist care
Show more FP Watch

Similar Articles

Navigate

  • Home
  • Current Issue
  • Archive
  • Collections - English
  • Collections - Française

For Authors

  • Authors and Reviewers
  • Submit a Manuscript
  • Permissions
  • Terms of Use

General Information

  • About CFP
  • About the CFPC
  • Advertisers
  • Careers & Locums
  • Editorial Advisory Board
  • Subscribers

Journal Services

  • Email Alerts
  • Twitter
  • RSS Feeds

Copyright © 2023 by The College of Family Physicians of Canada

Powered by HighWire